Hedge Funds Are Heavily Shorting This AI Stock: Should You Buy, Wait, or Avoid?
The stock is down about 29% year-to-date, despite strong earnings.
The stock is down about 29% year-to-date, despite strong earnings.
Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obe...
Wall Street is on edge after Friday's sharp reversal ahead of a week defined by Trump's Fed pick, jobs data and more Big...
The Dow rose, while the S&P 500 and Nasdaq fell, as the stock market weighed the latest Big Tech earnings.